Evidence map›Paper›PMID 38986017›Full record

ArticleAngewandte Chemie (International ed. in English)2024

Potent and Selective Oxidatively Labile Ether-Based Prodrugs through Late-Stage Boronate Incorporation.

Paul J Geaneotes, Chasity P Janosko, Cephas Afeke, Alexander Deiters, Paul E Floreancig

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Strategy-Level Prodrug Synthesis.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paul J GeaneotesDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, USA.ORCID 0009-0007-0462-5330
Chasity P JanoskoDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, USA.
Cephas AfekeDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, USA.
Alexander DeitersDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, USA.ORCID 0000-0003-0234-9209
Paul E FloreancigDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, USA.ORCID 0000-0001-9626-3187

Funding

Conditional Control of Drug Function Through α-Boryl Ether OxidationR01GM127153 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEITERS, ALEXANDER, FLOREANCIG, PAUL E · 2019 to 2022
$1.5M
NIGMS NIH HHS R01 GM127153NIGMS NIH HHS R01GM127153
6 · The paper itself

Abstract

This manuscript describes a new strategy for prodrug synthesis in which a relatively inert ether group is introduced at an early stage in a synthetic sequence and functionalized in the final step to introduce a prodrug-activating group through a chemoselective process. Boryl allyloxy (BAO) ether groups are synthesized through several metal-mediated processes to form entities that are readily cleaved under oxidative conditions commonly found in cancer cells. The high cleavage propensity of the BAO group allows for ether cleavage, making these compounds substantially more hydrolytically stable in comparison to acyl-linked prodrugs while retaining the ability to release alcohols. We report the preparation of prodrug analogues of the natural products camptothecin and pederin from acetal precursors that serve as protecting groups in their synthetic sequences. The BAO acetal groups cleave in the presence of hydrogen peroxide to release the cytotoxic agents. The pederin-based prodrug shows dramatically greater cytotoxicity than negative controls and outstanding selectivity and potency toward cancer cell lines in comparison to non-cancerous cell lines. This late-stage functionalization approach to prodrug synthesis should be applicable to numerous systems that can be accessed through chemoselective processes.

Indexed as

Boronic AcidsEthersOxidation-ReductionProdrugsAntineoplastic AgentsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructureAntineoplastic AgentsBoronic AcidsEthersProdrugsBoronCytotoxicityMetathesisOxidationProdrugs

Identifiers

PMID38986017
PMCPMC12228984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.